Eli Lilly Expands Beyond GLP-1 With RNA Cancer AI And Obesity Bets
✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source
Eli Lilly is expanding its focus beyond GLP-1. The company is making investments in RNA cancer technology and obesity treatments, in addition to artificial intelligence. These moves indicate a diversification of Eli Lilly's portfolio.